Healthcare & Biotech

SHERIDAN, WYOMING – May 7, 2025 – Convatec, a global leader in medical technologies focused on chronic condition management, has received regulatory approval for ConvaNiox™, a first-of-its-kind nitric oxide-generating multimodal dressing technology. This innovative product aims to significantly improve outcomes for patients with diabetic foot ulcers (DFUs), offering a powerful solution to an underserved segment of the wound care market.

The full launch of ConvaNiox™ is set for 2026, with an initial rollout scheduled for later this year in key European markets. This new technology combines the potent antimicrobial and antibiofilm properties of nitric oxide to accelerate healing in chronic wounds, particularly DFUs. In clinical trials, ConvaNiox™ demonstrated remarkable results, healing DFUs 60% faster than standard treatments.

SHERIDAN, WYOMING – May 7, 2025 – Convatec, a leading provider of medical products and technologies, has expressed its support for the postponement of Local Coverage Determinations (LCDs) for skin substitutes in the United States until January 2026. This delay, made by the Centers for Medicare & Medicaid Services (CMS), ensures that Medicare patients in the US will continue to have access to InnovaMatrix®, a trusted product for treating diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs).

SHERIDAN, WYOMING – May7, 2025 – Drägerwerk AG & Co. KGaA has shown significant growth in its order intake during the first quarter of 2025, marking a strong start to the year despite a seasonally weaker operating result. With order intake reaching approximately EUR 861 million, the company exceeded its prior-year figures by EUR 50 million. Net sales closely mirrored last year's numbers, while operating results remained narrowly positive, reflecting both challenges and opportunities across global markets.

SHERIDAN, WYOMING – May 7, 2025 – Dräger, a global leader in safety technology, has launched the Alcotest 7000, an advanced alcohol screening device that is set to redefine safety protocols in law enforcement, Department of Transportation (DOT) compliance, and workplace safety initiatives. This innovative new product comes with dual-function capability, designed to meet the evolving needs of both criminal justice and safety-sensitive industries. The Alcotest 7000 is poised to enhance accuracy, streamline operations, and contribute to safer roads and workplaces.

Dual-Mode Testing for Enhanced Flexibility

The Alcotest 7000 is a versatile device that offers two modes of operation, allowing it to be used in various environments for a broad range of applications. Whether it’s in high-volume screening situations or precise, individual assessments, the Alcotest 7000 ensures reliable and accurate results every time.

SHERIDAN, WYOMING – May 7, 2025 – Dräger, a global leader in medical and safety technology, has been awarded a significant five-year contract by the U.S. Department of Veterans Affairs (VA) under the Non-Expendable (NX) Equipment Program. This contract focuses on providing cutting-edge surgical lighting systems and equipment boom solutions to VA medical facilities, streamlining procurement and enhancing operational efficiency across the healthcare system.

Strategic Importance of the VHA Contract

The newly awarded contract (#36C10G24D0105) will allow Veterans Health Administration (VHA) medical centers to access Dräger's advanced surgical lighting and equipment booms via the National Equipment Catalog (NEC). By offering a streamlined purchasing process, this contract will not only support the operational needs of VA facilities but also drive long-term value in terms of cost efficiency and clinical outcomes.

SHERIDAN, WYOMING – May 7, 2025 – Mindray, a global leader in medical technologies, has announced the launch of its new-generation FA-N Series, an advanced automatic microbial culture system designed to transform the diagnosis of bloodstream infections. This cutting-edge system offers optimized workflows, faster detection times, and enhanced accuracy, addressing key challenges faced by clinical microbiologists and improving patient outcomes.

SHERIDAN, WYOMING – May 7, 2025 – Terumo Corporation, a global leader in medical technology, has unveiled its "Terumo Group Statement on Nature," a comprehensive guideline aimed at enhancing the company's commitment to the conservation and restoration of natural environments. This initiative is a strategic step in Terumo's ongoing efforts to reduce its environmental footprint and promote sustainability within its operations and value chain.

Strengthening Environmental Responsibility

With the establishment of the "Terumo Group Statement on Nature," the company emphasizes its corporate responsibility to mitigate the environmental impact of its business activities. Terumo acknowledges its reliance on natural resources such as water and recognizes the broader impacts of its operations on biodiversity and ecosystems. By focusing on the reduction of environmental harm and promoting nature conservation, Terumo aligns its operations with global sustainability trends.

SHERIDAN, WYOMING – May 7, 2025 – Terumo Blood and Cell Technologies (Terumo BCT), a leading medical technology company, has announced the appointment of Patrick Daly as its new Chief Business Officer. Daly, a seasoned veteran with over 30 years of experience in the healthcare industry, will play a crucial role in driving business growth and enhancing Terumo BCT's strategic initiatives.

With a distinguished career in business development and strategic partnerships, Daly brings valuable expertise to the company as it continues to expand its portfolio of solutions for blood collection, therapeutic apheresis, and cell therapy. His leadership is expected to accelerate Terumo BCT's goals for innovation, market integration, and enterprise expansion.

SHERIDAN, WYOMING – May 7, 2025 – Intuitive (NASDAQ: ISRG), a global leader in robotic-assisted surgery, today announced the U.S. Food and Drug Administration (FDA) has granted clearance for its da Vinci Single Port (SP) surgical system for transanal local excision/resection. This clearance, which builds upon previous FDA approvals for transabdominal colorectal procedures, further enhances the capabilities of the da Vinci SP system, supporting minimally invasive surgery via natural orifice access.

Advancing Colorectal Surgery with Innovative Technology

The da Vinci SP system is designed to improve precision in surgeries that require access to narrow body cavities, such as those in the lower pelvis and rectum. By allowing surgeons to control up to three multi-jointed instruments and a high-definition articulating camera through a single entry point, the system offers enhanced freedom of movement in these smaller, more confined spaces.

SHERIDAN, WYOMING – May 7, 2025 – Intuitive (Nasdaq: ISRG), a global leader in minimally invasive care and robotic-assisted surgery, has announced its financial results for the first quarter of 2025, showcasing impressive growth and a strong strategic position in the healthcare technology market. The company's financial performance highlights robust growth in surgical procedures, system placements, and revenue, underscoring its leadership in the evolving field of robotic-assisted surgery.

Robust Growth in da Vinci Procedures and System Placements

In Q1 2025, Intuitive saw a 17% year-over-year increase in worldwide da Vinci procedures, reflecting the growing adoption of its robotic surgery systems. This increase is part of a broader trend towards minimally invasive surgery, where precision, reduced recovery times, and improved patient outcomes are driving demand.